Investing.com - Stoke Therapeutics (NASDAQ: STOK) reported first quarter EPS of $-0.57, $0.05 better than the analyst estimate of $-0.62. Revenue for the quarter came in at $4.2M versus the consensus estimate of $3.21M.
Stoke Therapeutics's stock price closed at $12.02. It is up 173.80% in the last 3 months and up 0.59% in the last 12 months.
Stoke Therapeutics saw 2 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Stoke Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Stoke Therapeutics's Financial Health score is "fair performance".
Check out Stoke Therapeutics's recent earnings performance, and Stoke Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar